Potentially inappropriate anticholinergic medication use in older adults with dementia.
OBJECTIVE
To examine the prevalence and predictors of potentially inappropriate anticholinergic medication use in older adults with dementia.


METHODS
A cross-sectional study.


METHODS
United States, 2009-2010.


METHODS
Medical Expenditure Panel Survey household component participants aged 65 years or older identified as having dementia and using potentially inappropriate anticholinergic medication.


METHODS
Prevalence and predictors of potentially inappropriate anticholinergic medication use as per the updated 2012 American Geriatrics Society Beers criteria.


RESULTS
A total of 3.78 million older adult patients (95% confidence interval [CI] 3.17 million to 4.38 million) were identified as having dementia, for an overall prevalence of 4.81%. Of those patients, an estimated 1.02 million (95% CI 0.70 million to 1.30 million) were reported to use potentially inappropriate anticholinergic medications, for an overall prevalence of 26.95% (95% CI 20.10% to 33.79%). The most frequently prescribed drugs were oxybutynin, solifenacin, paroxetine, tolterodine, promethazine, and cyclobenzaprine. Multivariable logistic analysis revealed that those patients with the need characteristics of self-reported anxiety, mood disorders, and "fair/poor" general health status had increased odds of potentially inappropriate anticholinergic use, while patients with the predisposing characteristic of being aged 75-84 years had decreased odds of potentially inappropriate anticholinergic use.


CONCLUSIONS
More than one in four older adults with dementia were found to use potentially inappropriate anticholinergics. Given the adverse cognitive effects of these medications, there is a strong need to monitor and optimize their use in older adult patients with dementia.
Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Texas Medical Center, Houston, TX.
Nandita
N
Kachru
Department of Epidemiology, College of Public Health, University of Iowa, Iowa City.
Ryan M
RM
Carnahan
Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Texas Medical Center, Houston, TX.
Michael L
ML
Johnson
Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Texas Medical Center, Houston, TX. Electronic address: rraparasu@uh.edu.
Rajender R
RR
Aparasu
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D018680:Cholinergic Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D003430:Cross-Sectional Studies; D003704:Dementia / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology*; D017723:Drug Utilization Review; D005260:Female; D006801:Humans; D057970:Inappropriate Prescribing; D016015:Logistic Models; D008297:Male; D008508:Medication Errors / Q000517:prevention & control*; D015999:Multivariate Analysis; D016017:Odds Ratio; D019338:Polypharmacy; D015995:Prevalence; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D018680:Cholinergic Antagonists